Through the agreement, Hitachi Medical will market, sell and service the Hi Art system, which facilitates highly precise, computed tomography-guided radiation therapy for a wide range of clinical indications.
Fred Robertson, CEO of TomoTherapy, said: “Hitachi Medical’s national infrastructure and reputation for excellent technical and customer support will enhance our ability to service all hospitals in Japan that are currently using TomoTherapy technology.
“Additionally, this agreement represents a significant opportunity for us to reach new customers, and help advance the quality of cancer care across Japan, the second largest radiation therapy marketplace in the world.”